# NCT05256290 (NCT05256290)

> Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05256290
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Black Diamond Therapeutics, Inc.
- Conditions: Non-Small Cell Lung Cancer; Advanced Non-Small Cell Squamous Lung Cancer; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Cancer; NSCLC; Advanced Lung Carcinoma; Epidermal Growth Factor Receptor C797S; Epidermal Growth Factor Receptor G719X; EGF-R Positive Non-Small Cell Lung Cancer; EGFR-TKI Resistant Mutation
- Interventions: silevertinib (BDTX-1535) monotherapy
- Enrollment: 200
- Primary outcome: Phase 1 Dose Escalation: To determine the maximum tolerated dose (MTD), if one exists, and the preliminary recommended Phase 2 dose(s) (RP2D[s]) of silevertinib (BDTX-1535)
- Primary outcome: Phase 2: To assess antitumor efficacy of silevertinib (BDTX-1535)

## Commentary we found

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05256290